

This meeting is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute on Aging (NIA) of the National Institutes of Health under Award Number R13AR070644. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

GENERAL MEETING INFORMATION

Registration

Registration desks will be open for new registrants in the Palais des congr s in the Registration Hall, Viger Hall, Level 2 on **Thursday, September 27 from 7:00 am – 6:00 pm.**

Speaker Ready Room

Speakers must check into the Speaker Ready Room in advance of their presentation. At that time, speakers may review their slides. The Speaker Ready Room is located in Room 514 A in the Palais des congr s. The Speaker Ready Room will be open on **Thursday, September 27 from 7:00 am – 5:00 pm**

Organizing Committee

Jennifer Westendorf, Ph.D.
David Findlay, Ph.D.
Nancy Lane, M.D.

Support

This activity is supported by educational funding donations provided by:

Flexion
Scanco Medical

CONTINUING MEDICAL EDUCATION



This activity has been planned and implemented by Creighton University Health Sciences Continuing Education (HSCE) and The American Society for Bone and Mineral Research (ASBMR) for the advancement of patient care. Creighton University Health Sciences Continuing Education is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

AMA PRA Statement

Creighton University Health Sciences Continuing Education designates this live activity for a maximum of 6.25 *AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

AAPA accepts AMA category 1 credit for the PRA from organizations accredited by ACCME.

Online Evaluation to Receive CME

The online evaluation to receive CME will be available beginning Friday, October 5. You will receive an email from ASBMR with instructions on how to claim credit.

Target Audience

This meeting will bring together national and international investigators currently working in the field of osteoarthritis as well as young and established investigators, industry scientists, NIH intramural scientists and program staff, clinicians, endocrinologists and basic and translational researchers.

Learning Objectives

Upon returning home from the meeting, participants should be able to:

1. Provide attendees with state of the art knowledge regarding the state of osteoarthritis research.
2. Interpret the interaction of basic, translational, and clinical research in skeletal and osteoarthritis research.
3. Discover new and innovative treatment advancing in the field of osteoarthritis.

ASBMR Expectations of Authors and Presenters

Through ASBMR meetings, the Society promotes excellence in bone and mineral research. Toward that end, ASBMR expects that all authors and presenters affiliated with the ASBMR Symposium on Skeletal Contributions to Joint Degeneration and Osteoarthritis will provide informative and fully accurate content that reflects the highest level of scientific rigor and integrity.

ASBMR depends upon the honesty of the authors and presenters and relies on their assertions that they have had sufficient full access to the data and are convinced of its reliability.

Furthermore, ASBMR expects that:

- Authors and presenters will disclose any conflicts of interest, real or perceived.
- Authors of an abstract describing a study funded by an organization with a proprietary or financial interest must affirm that they had full access to all the data in the study. By so doing, they accept complete responsibility for the integrity of the data and the accuracy of the data analysis.
- The content of abstracts, presentations, slides and reference materials must remain the ultimate responsibility of the author(s) or faculty.
- The planning, content and execution of abstracts, speaker presentations, slides, abstracts and reference materials should be free from corporate influence, bias or control.
- All authors and presenters (invited and abstracts-based oral and poster presenters) should give a balanced view of therapeutic options by providing several treatment options, whenever possible, and by always citing the best available evidence.

Disclosure Policy

The ASBMR is committed to ensuring the balance, independence, objectivity and scientific rigor of all its individually sponsored or industry-supported educational activities. Accordingly, the ASBMR adheres to the requirement set by ACCME that audiences at jointly-sponsored educational programs be informed of a presenter's (speaker, faculty, author, or planner) academic and professional affiliations, and the disclosure of the existence of any significant financial interest or other relationship a presenter or their spouse has with any proprietary entity over the past 12 months producing, marketing, re-selling or distributing health care goods or services, consumed by, or used on patients, with the exemption of non-profit or government organizations and non-health care related companies. When an unlabeled use of a commercial product, or an investigational use not yet approved for any purpose, is discussed during the presentation, it is required that presenters disclose that the product is not labeled for the use under discussion or that the product is still investigational. This policy allows the listener/attendee to be fully knowledgeable in evaluating the information being presented. The On-Site Program book will note those speakers who have disclosed relationships, including the nature of the relationship and the associated commercial entity.

Disclosure should include any affiliation that may bias one's presentation or which, if known, could give the perception of bias. This includes relevant financial affiliations of a spouse or partner. If an affiliation exists that could represent or be perceived to represent a conflict of interest, this must be reported in the abstract submission program by listing the name of the commercial entity and selecting the potential conflict(s) by clicking in the box next to the relationship type. Disclosures will be printed in the program materials. These situations may include, but are not limited to: (1) Grant/Research Support; (2) Consultant; (3) Speakers' Bureau; (4) Major Stock Shareholder; (5) Other Financial or Material Support.

Copyright

Abstracts submitted to the ASBMR 2018 Annual Meeting and presented at the ASBMR Symposium on Skeletal Contributions to Joint Degeneration and Osteoarthritis are copyrighted by the American Society for Bone and Mineral Research. Reproduction, distribution, or transmission of the abstracts in whole or in part, by electronic, mechanical, or other means, or intended use, is prohibited without the express written permission of the American Society for Bone and Mineral Research.

Disclaimer

All authored abstracts, findings, conclusions, recommendations, or oral presentations are those of the author(s) and do not reflect the views of the ASBMR or imply any endorsement. No responsibility is assumed, and responsibility is hereby disclaimed, by the American Society for Bone and Mineral Research for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of methods, products, instructions, or ideas presented in the materials herein (2018 Abstracts). Independent verification of diagnosis and drug dosages should be made. Discussions, views, and recommendations as to medical procedures, choice of drugs, and drug dosages are the responsibility of the authors.

Audio and Video Recording

ASBMR expects that attendees respect each presenter's willingness to provide free exchange of scientific information without the abridgement of his or her rights or privacy and without the unauthorized copying and use of the scientific data shared during his or her presentation. In addition, ASBMR expects that attendees will respect exhibitors' desires not to have their products or booths photographed or video-recorded.

The use of cameras, audio-recording devices, and video-recording equipment is strictly prohibited within all Scientific Sessions, the Exhibit Halls, and Poster Sessions without the express written permission of both the ASBMR and the presenter/exhibitor. Unauthorized use of the recording equipment may result in the confiscation of the equipment or the individual may be asked to leave the session or Exhibit Hall. These rules are strictly enforced.

Meeting Evaluation

An online evaluation form for the ASBMR Symposium on Skeletal Contributions to Joint Degeneration and Osteoarthritis will be available on the ASBMR Website at www.asbmr2018.org after the meeting and sent to you via email. Your participation in this evaluation is extremely important to us. Please take a moment to complete the evaluation of this meeting to aid in planning future meetings. Thank you in advance for your feedback.

Use of ASBMR Name and Logo

ASBMR reserves the right to approve the use of its name in all materials disseminated to the press, public and professionals. The ASBMR name, meeting name, and meeting logo may not be used without permission. Use of the ASBMR logo is prohibited without the express written permission of the ASBMR Executive Director. All ASBMR corporate supporters and exhibitors should share their media outreach plans with the ASBMR before release.

No abstract presented at the ASBMR Symposium may be released to the press before its official presentation date and time. Press releases must be embargoed until one hour after the presentation.

Future ASBMR Annual Meeting Dates

ASBMR 2019 Annual Meeting

Orange County Convention Center, Orlando, FL, USA
September 20-23, 2019

ASBMR 2020 Annual Meeting

Washington State Convention Center, Seattle, WA, USA
September 11 – 14, 2020

THURSDAY, SEPTEMBER 27, 2018

CONTINENTAL BREAKFAST

8:00 am – 9:00 pm

513 Foyer

RISK FACTORS FOR OA

9:00 am – 10:30 am

Room 513

Co-Chairs:

Marian Hannan, Ph.D., HSL Institute for Aging Research and Harvard Medical School, United States
Linda Sandell, Ph.D., Washington University in St. Louis School of Medicine, United States

9:00 am Epidemiology of OA

Grace Hsiao-Wei Lo, M.D., M.S., Baylor College of Medicine, United States

Disclosures: None

9:30 am Biomechanical Contributions to OA

Bruce Beynon, Ph.D., University of Vermont, United States

Disclosures: None

10:00 am Imaging Advances for Early Detection of Cartilage and Bone Damage in Joints

Gayle Lester, Ph.D., National Institute of Arthritis, Musculoskeletal and Skin Disease, United States

Disclosures: None

BREAK AND POSTER VIEWING

10:30 am – 11:15 am

513 Foyer

EMERGING BIOLOGY OF AGING AND INJURY IN OA

11:15 am – 12:45 pm

Room 513

Co-Chairs:

Frank Beier, Ph.D., University of Western Ontario, Canada
Marjolein van der Meulen, Ph.D., Cornell University, United States

11:15 am Subchondral Bone Remodeling and OA

Martine Cohen-Solal, M.D., Ph.D., Centre Viggo Petersen, France

Disclosures: None

11:45 am Animal Models of OA

Christopher Little, Ph.D., The University of Sydney, Australia

Disclosures: None

12:15 pm Genetics of Cartilage Repair and Osteoarthritis – Result of 1000 Mouse Surgeries

Linda Sandell, PhD, C-IAYT, Washington University, United States

Disclosures: None

LUNCH AND POSTER VIEWING

12:45 pm – 1:45 pm

513 Foyer

CARTILAGE AND BONE CROSSTALK IN OA

1:45 pm – 3:25 pm

Room 513

Co-Chairs:

Tamara Alliston, Ph.D., University of California, San Francisco, United States

David Findlay, Ph.D., University of Adelaide, Australia

1:45 pm TGFb Functions in OA Pathophysiology and Treatment

Xu Cao, Ph.D., Johns Hopkins University, USA

Disclosures: None

2:10 pm TGFbR Functions in OA

Tieshi Li, Ph.D., Rush University Medical Center, United States

Disclosures: None

2:35 pm Bone Marrow Lesions in Osteoarthritic Joints

Julia Kuliwaba, Ph.D., The University of Adelaide, Australia

Disclosures: None

3:00 pm Tissue Mechanical Deficiencies Detected in Both Articular Cartilage and Subchondral Trabecular Bone in Osteoarthritic Human Knees

Yizhong Hu, M.S., Columbia University, United States

Disclosures: None

BREAK

3:25 pm – 3:45pm

513 Foyer

CLINICAL CONUNDRUMS

3:45 pm – 5:15 pm

Room 513

Co-Chairs:

Nancy Lane, M.D., University of California, Davis Medical Center, United States

Christopher Little, Ph.D., The University of Sydney, Australia

3:45 pm Bisphosphonate Treatment of OA Lesions

Graeme Jones, Ph.D., Menzies Institute for Medical Research, Australia

Disclosures: None

4:15 pm Wnt Signaling in OA: From Clinical Genetics to Clinical Trials

Maripat Corr, M.D., University of California, San Diego School of Medicine, United States

Disclosures: None

4:45 pm Circulating Sclerostin Is Associated with Preserved Joint Space in Non-weight Bearing Joints in a Population Enriched for High Bone Mineral Density

April Hartley, Bristol Medical School, University of Bristol, United Kingdom

Disclosures: None

CLOSING REMARKS

5:15 – 5:20 pm

Room 513

RECEPTION AND POSTER VIEWING

5:20 pm – 6:00 pm

513 Foyer
